LID.L Regulatory News (LID)

3 Oct 2006 07:00

For immediate release 3 October 2006 LiDCO Group Plc ("LiDCO" or "the Company") Investor open half day on R&D at St Thomas' Hospital LiDCO the cardiovascular monitoring company is pleased to announce that it isholding an open day for investors and analysts to be held at St Thomas'hospital, London, on Monday 9 October, from 2pm until 5pm.The purpose of the afternoon is to brief the City audience on LiDCO's R&Dstrategy including details of the latest software release (Version 4) and thenew research and clinical audit product LiDCOview. Version 4, in combinationwith the LiDCOview will demonstrate how our technology has made a significantleap forward compared with the market's current older, non-PC based measuringdevices.The Company will also be showing investors the new URINFO¢â€ž¢ system fromMed-Dynamix with whom LiDCO have recently signed an exclusive agreement todistribute in the UK and Ireland.Brief talks will be given by clinicians and nurses who are using the technologyas well as by the Company to demonstrate both the business and clinical casefor our technology and how it has enhanced patient outcomes and saved lives.No financial information will be provided during the open day.Analysts, investors and potential investors are very welcome and should youwish to attend please call the Company Secretary; details below. - ENDS - For more information please contact:LiDCO Group Plc Tel: +44 (0)20 7749 1500 Rob Lamb Company Secretary Terry O'Brien - Chief Executive Hugh McGarel-Groves - Finance Director Buchanan Communications Tel: +44 (0)20 7466 5000 Tim Anderson, James Strong LiDCO's interim results and investor presentation `LiDCO's Interim Results -six months ended 31st July 2006 will be available on the LiDCO website (www.lidco.com) on the 18th October 2006.Notes for EditorsAbout LiDCO Group PlcLiDCO is a UK-based AIM-traded developer, manufacturer and leading supplier ofminimally invasive, computer-based hemodynamic monitoring equipment anddisposables used primarily for the management of critical care andcardiovascular risk hospital patients. Use of LiDCO's technology has been shownto significantly reduce the complications (particularly infections) and costsassociated with major surgery. The technology was invented in the Department ofApplied Physiology based at St Thomas' Hospital, London. The Company'smanufacturing facility is in Hoxton, London N1 and its current products are:¢â‚¬¢ LiDCOplus and PulseCO monitors: computer-based platforms for displaying arange of real-time, continuous hemodynamic parameters including cardiac output,oxygen delivery and fluid volume;¢â‚¬¢ LiDCO disposables: used in conjunction with the LiDCOplus Monitor toaccurately determine cardiac output in a minimally-invasive manner.Distribution Network:The Company has now achieved registration of its products in 14 markets inEurope, the USA, Brazil and Japan. It sells direct in the UK and USA, andelsewhere through a worldwide network of specialty critical care distributors.ENDLIDCO GROUP PLC